Skip to main content
Premium Trial:

Request an Annual Quote

Oncodesign, Eisai Reach Deal to Assess Eribulin

NEW YORK (GenomeWeb News) – Oncodesign today announced an agreement with Eisai to assess the use of Halaven Injection (eribulin) in earlier line treatment of metastatic breast cancer. 

Oncodesign will conduct in vivo pharmacology studies and Eisai will perform gene expression profiling analysis using Oncodesign's patient-derived xenograft models to evaluate Eisai's Halaven, a non-taxane microtubule dynamics inhibitor. Oncodesign could receive up to €1.25 million ($1.56 million) in revenue for its contributions and has received €900,000 to date, it said.

Based in Dijon, France, Oncodesign supports drug development firms discovering therapeutic molecules directed against cancer and other diseases. 

 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.